The tumor reduction correlated with resolution of the patient's symptomsof pain and digestive problems. "The cancer isn't gone," emphasized NeoPlasInnovation Director of Research Dr. Stephen B. Cantrell. "There are stillseveral metastatic lesions to address, but this kind of response is virtuallyunheard of in pancreatic cancer. At the very least, we're looking at hishaving many, many months of added survival with a quality of life he can trulyenjoy."

The patient's daughter discussed her father's treatment, saying "He beganthe NeoPlas treatment after he became too ill to complete his final course ofradiation following chemotherapy." She added, "Since then, he has been able toresume work two to three hours a day, go to lunch with other men and even takea ten-day trip to Europe with my brother."

The cholesterol drug Lovastatin is a key part of this treatment that hasarrested or eradicated tumors in 78% of initial patients. The first persontreated with the investigative protocol in 2000 had stage 4 melanoma; heremains disease-free today.

Based on experience and relevant lab research to date, staff membersexpect the best results for several malignancies. In addition to pancreaticcancer and melanoma, they include colon cancer, renal (kidney) cancer,mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcomaand malignant fibrous histiocytoma.

Fatigue is the most notable side effect of NeoPlas Innovation's cancertreatment. Most patients never experience effects commonly affiliated withchemotherapy or radiation (nausea, vomiting, hair loss, bone marrowsuppression or immune system suppression). An experienced physician prescribesand monitors the outpatient treatment.

A web site, http://www.neoplas.org, provides answers to common questionsand a screening tool. Individuals can reach NeoPlas at 615-371-8100 or bye-mailing office@neoplas.org.

For an interview with Dr. Cantrell, call 615-371-8100 or e-mailoffice@neoplas.org.

SOURCE NeoPlas Innovation